Latest Health News

ECS Botanics is set to launch AVANI AVA, a new medicinal cannabis range specifically designed for women’s health, aiming to capture a growing market segment with targeted formulations.

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

Island Pharmaceuticals has submitted critical responses to the FDA, advancing the development of its antiviral Galidesivir under the Animal Rule pathway. The company awaits FDA feedback expected by early January 2026, setting the stage for upcoming Marburg virus studies.

OMG Group has reported a record-breaking November with $720,000 in sales, driving a 68% revenue increase year-to-date. Strong ecommerce and retail growth set the stage for a promising summer season.

Nuix Limited has announced its acquisition of Paris-based graph intelligence firm Linkurious for up to €20 million, aiming to enhance its AI-driven data analytics capabilities and expand its global footprint.

Queste Communications reported a slight net cash outflow from operations in November 2025 but maintains robust liquidity supported by a substantial loan facility and liquid ASX-listed investments.

QPM Energy Limited has had its trading suspension lifted following the announcement of a strategic investment term sheet and a capital raising, signaling renewed momentum for the energy company.

Microequities Asset Management Group delivered a robust November trading update, driven by strong returns in its Pure Microcap Value Fund and a final performance payment from a special purpose vehicle, pushing half-year profits above last year’s level.

Mach7 Technologies has inked a five-year subscription agreement with UnityPoint Health, marking the first commercial deployment of its new Flamingo Architecture and setting the stage for significant recurring revenue growth.

BTC Health has reissued its Chairman’s Address with added financial details, highlighting a strategic shift towards diversified medical products and a strong start to FY26 with 36% revenue growth.

LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.